BIOMEDICAL DIAGNOSTICS
ActiveFinancials · financial year 2025, full format
Annual accounts 2025 filed on 19-06-2026 at the NBB all 22 filings
Every figure per financial year
The operating result for 2025 is 11% lower than in 2024 and the lowest since 2021. It is the third fall in a row.
The turnover shown is an estimate from the gross margin.
Staff
| Item | 31-12-2021 | 31-12-2022 | 31-12-2023 | 31-12-2024 | 31-12-2025 |
|---|---|---|---|---|---|
| Employees at the balance-sheet date | 6 | 7 | 7 | 8 | 10 |
| full-time | 3 | 4 | 4 | 5 | 6 |
| part-time | 3 | 3 | 3 | 3 | 4 |
| in full-time equivalents | 4.9 | 5.9 | 5.9 | 6.9 | 8.4 |
| Average over the year, in full-time equivalents | 5.7 | 5.3 | 5.8 | 6.7 | 7.4 |
| On a permanent contract | 6 | 7 | 7 | 8 | 10 |
| Joined | 0 | 1 | - | 1 | 3 |
| Left | 1 | 1 | - | 0 | 1 |
Source: social balance sheet in the 2021 to 2025 annual accounts
Investments
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Tangible fixed assets | €20,800 | €123,271 | €15,558 | €29,900 | €72,642 |
| Financial fixed assets | - | - | €34 | €60 | €60 |
| Depreciation and write-downs of the year | €20,632 | €30,174 | €21,244 | €19,771 | €24,455 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | €0.09m | €0.03m | €0.04m | €0.02m | €0.005m | ▼ 71.5% |
| Remuneration, social security and pensions62 | - | - | - | €0.7m | €0.6m | €0.7m | €0.8m | €0.9m | ▲ 13.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €0.04m | €0.05m | €0.03m | €0.02m | €0.03m | €0.02m | €0.02m | €0.02m | ▲ 23.7% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | - | €0.002m | -€0.001m | -€0.001m | €0.02m | -€0.03m | - |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | - | - | - | -€0.003m | - | - | - | -€0.05m | - |
| Other operating charges640/8 | - | - | - | €0.001m | €0.001m | €0.002m | €0.004m | €257 | ▼ 93.4% |
| Non-recurring operating charges66A | - | - | - | - | - | €0.001m | €0.04m | €0.008m | ▼ 79.5% |
| Gross operating margin9900 | €1.5m | €1.4m | €1.2m | €1.3m | €1.5m | €1.4m | €1.4m | €1.3m | ▼ 4.9% |
| Operating profit (loss)9901 | €0.8m | €0.7m | €0.6m | €0.6m | €0.9m | €0.7m | €0.5m | €0.4m | ▼ 11.4% |
| Financial income75/76B | - | - | - | €0.04m | €0.002m | €0.08m | €0.08m | €0.07m | ▼ 13.5% |
| Recurring financial income75 | €0.02m | €0.002m | €0.02m | €0.04m | €0.002m | €0.08m | €0.08m | €0.07m | ▼ 13.5% |
| Financial charges65/66B | - | - | - | €0.007m | €0.1m | -€233 | €0.02m | €0.009m | ▼ 59.0% |
| Recurring financial charges65 | €0.02m | €0.07m | €0.05m | €0.007m | €0.1m | -€233 | €0.02m | €0.009m | ▼ 59.0% |
| Profit (loss) for the period before taxes9903 | €0.8m | €0.6m | €0.5m | €0.7m | €0.8m | €0.8m | €0.5m | €0.5m | ▼ 9.8% |
| Income taxes67/77 | €0.06m | €0.06m | €0.04m | €0.2m | €0.2m | €0.2m | €0.1m | €0.1m | ▼ 8.9% |
| Profit (loss) for the period9904 | €0.8m | €0.6m | €0.5m | €0.5m | €0.6m | €0.6m | €0.4m | €0.3m | ▼ 10.1% |
| Profit (loss) for the period to be appropriated9905 | €0.8m | €0.6m | €0.5m | €0.5m | €0.6m | €0.6m | €0.4m | €0.3m | ▼ 10.1% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €1.9m | €1.8m | €1.8m | €1.7m | €1.7m | €2.6m | €3.0m | €3.5m | ▲ 16.9% |
| Fixed assets21/28 | €0.07m | €0.06m | €0.1m | €0.08m | €0.2m | €0.08m | €0.06m | €0.1m | ▲ 65.3% |
| Tangible fixed assets22/27 | €0.05m | €0.05m | €0.1m | €0.07m | €0.1m | €0.06m | €0.05m | €0.09m | ▲ 84.6% |
| Plant, machinery and equipment23 | - | - | - | €0.07m | €0.1m | €0.06m | €0.05m | €0.09m | ▲ 84.6% |
| Financial fixed assets28 | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | ▲ 0.4% |
| Current assets29/58 | €1.8m | €1.8m | €1.7m | €1.6m | €1.5m | €2.5m | €2.9m | €3.4m | ▲ 15.9% |
| Stocks and contracts in progress3 | €0.2m | €0.2m | €0.2m | €0.2m | €0.2m | €0.3m | €0.4m | €0.9m | ▲ 102% |
| Stocks30/36 | - | - | - | €0.2m | €0.2m | €0.3m | €0.4m | €0.9m | ▲ 102% |
| Amounts receivable within one year40/41 | €0.8m | €0.7m | €0.6m | €0.8m | €0.7m | €1.0m | €1.8m | €2.0m | ▲ 12.2% |
| Trade receivables40 | - | - | - | €0.8m | €0.7m | €1.0m | €0.7m | €0.9m | ▲ 30.1% |
| Other amounts receivable41 | - | - | - | €0.01m | €0.01m | €0.01m | €1.1m | €1.1m | ▲ 0.1% |
| Cash at bank and in hand54/58 | €0.9m | €0.8m | €0.9m | €0.5m | €0.6m | €1.2m | €0.7m | €0.5m | ▼ 27.8% |
| Deferred charges and accrued income490/1 | - | - | - | €0.03m | €0.005m | €0.005m | €0.02m | €0.004m | ▼ 77.3% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €1.9m | €1.8m | €1.8m | €1.7m | €1.7m | €2.6m | €3.0m | €3.5m | ▲ 16.9% |
| Equity10/15 | €0.8m | €0.9m | €0.5m | €0.6m | €1.1m | €1.8m | €2.1m | €2.5m | ▲ 16.0% |
| Contributions10/11 | €0.06m | €0.06m | €0.06m | €0.06m | €0.06m | €0.06m | €0.06m | €0.06m | = |
| Capital10 | - | - | - | €0.06m | €0.06m | €0.06m | €0.06m | €0.06m | = |
| Issued capital100 | - | - | - | €0.06m | €0.06m | €0.06m | €0.06m | €0.06m | = |
| Reserves13 | €0.7m | €0.8m | €0.4m | €0.5m | €1.1m | €1.7m | €2.1m | €2.4m | ▲ 16.4% |
| Non-distributable reserves130/1 | - | - | - | €0.006m | €0.006m | €0.006m | €0.006m | €0.006m | = |
| Legal reserve130 | - | - | - | €0.006m | €0.006m | €0.006m | €0.006m | €0.006m | = |
| Distributable reserves133 | - | - | - | €0.5m | €1.1m | €1.7m | €2.1m | €2.4m | ▲ 16.5% |
| Provisions and deferred taxes16 | €0.05m | €0.05m | €0.05m | €0.05m | €0.05m | €0.05m | €0.05m | - | - |
| Provisions for liabilities and charges160/5 | - | - | - | €0.05m | €0.05m | €0.05m | €0.05m | - | - |
| Other liabilities and charges164/5 | - | - | - | €0.05m | €0.05m | €0.05m | €0.05m | - | - |
| Amounts payable17/49 | €1.1m | €0.9m | €1.3m | €1.1m | €0.5m | €0.8m | €0.8m | €1.0m | ▲ 26.0% |
| Amounts payable within one year42/48 | €1.1m | €0.9m | €1.3m | €1.1m | €0.5m | €0.8m | €0.8m | €1.0m | ▲ 26.1% |
| Trade debts44 | €0.3m | €0.3m | €0.3m | €0.3m | €0.3m | €0.5m | €0.6m | €0.8m | ▲ 41.7% |
| Suppliers440/4 | - | - | - | €0.3m | €0.3m | €0.5m | €0.6m | €0.8m | ▲ 41.7% |
| Taxes, remuneration and social security45 | - | - | - | €0.3m | €0.1m | €0.3m | €0.2m | €0.2m | ▼ 11.3% |
| Taxes450/3 | - | - | - | €0.2m | €0.07m | €0.2m | €0.1m | €0.09m | ▼ 22.0% |
| Remuneration and social security454/9 | - | - | - | €0.1m | €0.08m | €0.1m | €0.1m | €0.1m | ▼ 2.4% |
| Other amounts payable47/48 | - | - | - | €0.4m | €0.001m | €0.001m | €0.001m | €0.001m | = |
| Accrued charges and deferred income492/3 | - | - | - | €0.004m | €0.01m | €0.03m | €0.005m | €0.005m | ▲ 0.5% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €781,289 | €586,729 | €499,400 | €490,080 | €590,228 | €603,045 | €378,092 | €339,858 | ▼ 10.1% |
| + Depreciation and write-downs630 | €43,368 | €45,508 | €27,546 | €20,632 | €30,174 | €21,244 | €19,771 | €24,455 | ▲ 23.7% |
| Operating cash flow (approximation) | €824,657 | €632,237 | €526,946 | €510,712 | €620,402 | €624,289 | €397,862 | €364,314 | ▼ 8.4% |
| Investment in fixed assets (approximation) | - | -€41,628 | -€74,167 | €6,373 | -€110,657 | €63,124 | -€2,987 | -€65,114 | ▼ 2,080% |
| Change in cash | - | -€66,686 | €66,530 | -€349,430 | €70,391 | €619,157 | -€523,831 | -€193,334 | ▲ 63.1% |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 31,368 companies had the same profile as BIOMEDICAL DIAGNOSTICS has now. Two years later, 93.5% were still going and 0.5% had gone bankrupt.
- Micro
- 20 years or older
- solvency 30% or more
- a profit of 5% of the balance sheet or more
Another 0.1% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of BIOMEDICAL DIAGNOSTICS itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 31,368 companies, not a prediction for BIOMEDICAL DIAGNOSTICS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Latest 10 of 22 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | full format | 19-06-2026 | 2026-00177557 | |
| 31-12-2024 | abbreviated format | 24-06-2025 | 2025-00171512 | |
| 31-12-2023 | abbreviated format | 19-06-2024 | 2024-00142946 | |
| 31-12-2022 | abbreviated format | 26-06-2023 | 2023-00157278 | |
| 31-12-2021 | abbreviated format | 30-06-2022 | 2022-20132113 | |
| 31-12-2020 | abbreviated format | 23-07-2021 | 2021-39000582 | |
| 31-12-2019 | abbreviated format | 09-07-2020 | 2020-28000383 | |
| 31-12-2018 | abbreviated format | 31-07-2019 | 2019-41400350 | |
| 31-12-2017 | abbreviated format | 16-07-2018 | 2018-33700003 | |
| 31-12-2016 | abbreviated format | 14-07-2017 | 2017-32100317 |